17 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
, transparency laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face … , as well as additional regulation on pharmaceutical transparency and reporting requirements, any of which could negatively impact our future
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws, and other healthcare laws … on pharmaceutical transparency and reporting requirements, any of which could negatively impact our future profitability and increase our compliance burden. We
424B5
BIAF
BioAffinity Technologies Inc
8 Mar 24
Prospectus supplement for primary offering
12:18pm
fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied … and increasing competition for prescription drugs, as well as additional regulation on pharmaceutical transparency and reporting requirements, any
424B5
6a55 3xleusghhqdoye
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
86e9v3 m7sf74
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
2pwbumj4
16 Nov 23
Shelf registration
5:23pm
DRS
t7uyto krd1z
14 Aug 23
Draft registration statement
12:00am
424B4
0nia6cw0
2 Sep 22
Prospectus supplement with pricing info
3:25pm
S-1
gn9 w9mszjt4n
25 Apr 22
IPO registration
6:16am
- Prev
- 1
- Next